ERBB2 and breast carcinoma: In 2020, Shanghai PerHum Therapeutics conducted an open-label, single-arm, and dose-escalation phase I clinical study to evaluate the safety, tolerability, and major therapeutic outcomes of CAR-modified autologous T cells in HER2 positive solid tumors including breast cancer (NCT04511871).